A shrinking market opportunity caused by “significant” COVID-related delays in the development program has led Coherus BioSciences, Inc. to terminate its CHS-305 Avastin (bevacizumab) biosimilar and return North American rights to partner Innovent Biologics.
“The clinical trials were difficult in a number of things, so we lost a substantial amount of time with the...






